Immunotherapy and CAR T-Cell Therapy: Stephen M. Ansell, MD, PhD


The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Stephen M. Ansell, MD, PhD, chair, Lymphoma Group, Mayo Clinic, about incorporating immunotherapies beyond chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

CAR T-cell therapy is associated with high rates of durable responses, but can be expensive and time consuming. As such, CAR T-cell therapy can elicit cures in a fraction of patients with NHL, Ansell adds.

However, data with immunotherapies, such as tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid), are also demonstrating high rates of long-term, durable remissions, Ansell explains. As such, the overall utility of novel immunotherapies remains an unanswered question in NHL, Ansell says. However, they might offer a more accessible and cheaper alternative to CAR T-cell therapy without compromising efficacy, Ansell concludes.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.